Funding for this research was provided by:
Health Research Council of New Zealand (13/242)
Received: 1 March 2021
Accepted: 28 October 2021
First Online: 3 December 2021
: Ethics approval details for individual STRIDER trials:New Zealand/Australia: New Zealand Health and Disability Ethics Committee (CEN/12/06/028/AM05), Royal Brisbane & Women’s Hospital Human Research Ethics Committee (HREC/14/ORBW/178), and King Edward Memorial Hospital Ethics Committee (2014071EW).Canada: University of British Columbia/Children’s and Women’s Health Centre of BC Research Ethics Board (H15–00899).The Netherlands: MET AMC (NL41894.018.14).The UK: 14.NE.0011.
: Not applicable.
: KG, WG, AS, and KL led STRIDER trials in New Zealand/Australia, the Netherlands, UK, and Canada, respectively. All authors except J. Limpens are members of the STRIDER Consortium. BWM (a member of the STRIDER consortium) is supported by a NHMRC Investigator grant (GNT1176437). BWM reports consultancy for Guerbet, has been a member of the ObsEva advisory board and hold Stock options for ObsEva. BWM has received research funding from Guerbet and Merck.